The cost of HIV disease in Northern Italy: The payer's perspective

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 3, 2011, Pages 211-217

  Rizzardini, Giuliano ^a   Restelli, Umberto ^b   Bonfanti, Paolo ^a   Porazzi, Emanuele ^b   Ricci, Elena ^a   Casartelli, Luca ^b   Foglia, Emanuela ^b   Carenzi, Laura ^a   Citterio, Paola ^a   Orlando, Giovanna ^a   Maselli, Carlo ^c   Croce, Davide ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b CREMS Centre for Research on Health Economics Social and Health Care Management Carlo Cattaneo University LIUC   (Italy)

^c L Sacco Hospital ^*  (Italy)

Author keywords

health care costs; HIV infection; retrospective study; risk factors

Indexed keywords

CD4 ANTIGEN;

ADULT; CELL COUNT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STATISTICAL SIGNIFICANCE; VIROTHERAPY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; ITALY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 79959759807     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31821fdee2     Document Type: Review

References (38)

1. Steinbrook R. Providing antiretroviral therapy for HIV infection. N Engl J Med. 2001;344:844-846. (Pubitemid 32222166)
2. Schackman BR, Gebo KA,Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44:990-997. (Pubitemid 44674030)
3. Mocroft A, Ledergerber B, Katlama C, et al. EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29. (Pubitemid 36835816)
4. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008; 372:293-299.
5. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376:49-62.
6. ISTAT, Istituto Nazionale di Statistica. Demographic statistics. Available at: www.demo.istat.it. Accessed July 26, 2010.
7. Istituto Superiore di Sanità.Aggiornamento delle nuove diagnosi di infezione da HIV e dei casi di AIDS in Italia. Available at: www.iss.it/binary/pres/cont/dic2008.1228391047.pdf. Accessed November 2010.
8. Lombardy Region General Health Directorate. 2007-2009 Lombardy Region Social Services and Health Care Plan.
9. Hill A, Gebo K. Predicting HIV care cost using CD4 counts from clinical trials. Am J Manag Care. 2007;13:524-528. (Pubitemid 47404429)
10. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS. 2010;24:2705-2715.
11. Krentz HB, Gill MJ. Cost of medical care for HIV infected patients within a regional population from 1997 to 2006. HIV Med. 2008;9:721-730.
12. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4,200 cells /microL) with HIV infection. HIV Med. 2004;5:93-98. (Pubitemid 38404662)
13. Krentz HB, Gill J. Despite CD4 cell count rebound the higher initial cost of medical care for HIV infected patients persist 5 years after presentation with CD4 cell counts less than 350 ml. AIDS. 2010;24:2750-2753.
14. Drummond FM, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. Cary, NC: Oxford University Press; 2005.
15. International Monetary Fund. World Economic Outlook Database, April .2010. Available at: http://www.imf.org/external/pubs/ft/weo/2010/01/weodata/ weorept.aspx?sy=2000&ey=2010&scsm=1&ssd=1&sort=country&ds= .&br=1&c=136&s=PCPI%2CPCPIPCH%2CPCPIE%2CPCPIEPCH&grp= 0&a=&pr1.x=58&pr1.y=14. Accessed July 27, 2010.
16. Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Statist. 1947;18:50-60.
17. Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. J Am Stat Ass. 1952;47:583-621.
18. Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare Expenditures. J Health Econ. 2004;23:525-542. (Pubitemid 38569537)
19. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ. 1999;18:153-171. (Pubitemid 29052479)
20. Ministero della Salute. Rapporto Annuale sull'Attività di Ricovero Ospedaliero-Dati SDO 2007. Available at: http://www.salute.gov.it/imgs/C-17- pubblicazioni-1152-allegato.pdf. Accessed March 2011.
21. ISTAT. Regional Dataset on Health. http://en.istat.it/sanita/sociosan/ index.html. Accessed March 2011.
22. Greub G, Ledergerber B, Battegay M, et al, for the Swiss HIV Cohort Study. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800-1805.
23. De Luca A, Bugarini R, Cozzi Lepri A, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously näve HIV infected subjects. Ann Intern Med. 2002;162:2125-2132. (Pubitemid 35168221)
24. Strader DB. Coinfection with HIV and Hepatitis C Virus in injection drug users and minority populations. Clin Infect Dis. 2005;41:(suppl 1): S7-S13. (Pubitemid 40863719)
25. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21:1073-1089. (Pubitemid 46763278)
26. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a crosssectional analysis of the U.S. Adult AIDS Clinical Trial Group. Clin Infect Dis. 2002;34:831-87.
27. Sulkowski MS, Moore RD, Metha SH, et al. Hepatitis C and progression of HIV disease. JAMA. 2002;288:199-206. (Pubitemid 34755280)
28. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV6HCV International Panel. AIDS. 2002;16:813-828. (Pubitemid 34409005)
29. Trevino A, Soriano V, Rodriguez C, et al. Changing rate of non-B subtypes and coinfection with hepatitis B/C viruses in newly diagnosed HIV-1 individuals in Spain. AIDS Res Hum Retroviruses. 2010. Doi: 10.1089/AID.2010.0247.
30. Rosen S, Ketlhapile M, Sanne I, et al. Cost to patients of obtaining treatment for HIV/AIDS in South Africa. S Afr Med J. 2007; 97:524-529. (Pubitemid 47091191)
31. Harling G, Bekker LG, Wood R. Cost of dedicated ART clinic. S Afr Med J. 2007;97:593-596.
32. McConnel CE, Stanley N, du Plessis JA, et al. The cost of a rapid-test VCT clinic in South Africa. S Afr Med J. 2005;95:968-971. (Pubitemid 43019888)
33. Cleary S, Okorafor O, Chita W, et al. Financing antiretroviral treatment and primary health care services. In: Ijumba P, Barron P, eds. South African Health Review 2005. Durban, South Africa: Health Systems Trust; 2005.
34. de Sousa Marques HH, Couttolenc BF, et al. Costs of care provided in a university hospital for children exposed to or infected with the HIV/AIDS. Cad. Saude Publica. 2007;23(suppl 3):S402-S413.
35. Hill AM, Smith C. Analysis of treatment costs for HIV RNA reductions and CD4 increases for Darunavir versus other antiretrovirals in treatmentexperienced, HIV infected patients. HIV Clin Trials. 2007;8:121-131. (Pubitemid 47121757)
36. Fleishman JA, Gebo KA, Reilly ED, et al. Hospital and outpatient health services utilization among HIV infectev adults in care 2000-2002. Med Care. 2005;43(suppl 9):11140-11152.
37. Garattini L, Tediosi F, Di Cinto E, et al. Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care. 2001;13:6733-6741.
38. POSIT. La persona con infezione da HIV in Italia. Rilevazione 2007- 2008-2009. Available at: www.posit-nadir.org/posti/ProfiloGenerale.aspx. Accessed November 2010.